A case of conversion therapy for pancreatic neuroendocrine tumor with liver metastasis using Surufatinib combined with CAPTEM

#3943

Introduction: The preferred treatment for p-NETs is radical surgical resection. To increase the possibility of R0 resection, clinicians have been interested in conversion therapy which induces the tumor regression. However, no prospective studies have revealed which patients and p-NETs subcategory are suitable for conversion therapy and the best conversion therapy project.

Aim(s): To test which patients and p-NETs subcategory are suitable for conversion therapy and the best conversion therapy project.

Materials and methods: A 49-year old woman who was diagnosed with pancreatic tail NETs with multiple metastases in the liver based on PET-CT. After MDT discussion, the patient was considered to be unable to receive radical surgery. Therefore, a preoperative conversion therapy projects of surufatinib combined with CAPTEM was given for four cycles (surufatinib 250mg, qd+capecitabine tablets 1.5g, bid, Day1-14+ temozolomide capsules 400mg, qd, Day10-14).

Conference:

Presenting Author: Wang Z

Authors: Xie Z, Wang Z, Cao D, Ke N,

Keywords: p-NETs, conversion therapy, surufatinib, CAPTEM,